Companies › AGTX

AGTX 10-K & 10-Q changes, risk factors and insider trading

Agentix Corp. · OTC · Biological Products, (No Diagnostic Substances) · CIK 1603345 · All filings on SEC.gov

Everything below is quoted or computed from Agentix Corp.'s public SEC filings. It is not a recommendation to buy or sell. Automated comparisons can contain errors; confirm with the original filing.

At a glance

0 / 0risk-factor paragraphs added / removed in latest 10-K
0new risk-factor headings
0Form 4 filings reporting open-market purchases (last 180 days)
0Form 4 filings reporting open-market sales (last 180 days)

Jump to: Annual report (10-K) · Quarterly report (10-Q) · Insider transactions · 13F holders

What changed in the latest 10-K

Comparing 10-K filed 2026-07-01 (period ending 2026-03-31) with 10-K filed 2025-07-16 (period ending 2025-03-31).

Risk Factors (10-K Item 1A)

0new paragraphs
0removed paragraphs
0reworded paragraphs
28 → 28words in section

The section in the latest 10-K reads in full:

As a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item.

No wording changes found in this section.

Full comparison: every changed paragraph (0)

Green = added, red = removed. Unchanged paragraphs and tables are not shown. Read the complete text in the original filing.

Management's Discussion & Analysis (MD&A) (10-K Item 7)

2new paragraphs
4removed paragraphs
6reworded paragraphs
1,157 → 1,039words in section

Largest changes (selected automatically by length and topic keywords; quoted verbatim, no commentary)

Reworded

Paragraph as it now reads, with added and removed wording marked:

For the year ended March 31, 2025,2026, cash from financing was $100,00$110,450 versus $93,000$100,000 for our year ended March 31, 2024.2025. Cash from financings during the year ended March 31, 20252026 and 2025, respectively, consisted of $110,450 and $100,000 from loan proceeds received. Cash from financings during the year ended March 31, 2024 consisted of $163,000 from loan proceeds received offset by our payment of $70,000 on our loans.
see in full comparison
Removed text
“For the year ended March 31, 2025 and 2024, we received R&D credits totaling $0 and $198,371 related to our R&D efforts that occurred at our Agentix Australia Pty Ltd entity. We did not receive any R&D credits for the comparable period ended March 31, 2025.”
see in full comparison
Reworded

Paragraph as it now reads, with added and removed wording marked:

For the year ended March 31, 2025,2026, general and administrative expenses were $69,898$68,072 as compared to $346,543$69,898 for our year ended March 31, 2024,2025, a decrease of $276,645. The decrease was mainly related to a decrease in royalty fee we incurred related to patents in the prior period, compared to the prior period.$1,826.
see in full comparison
Removed text
“For the year ended March 31, 2025, professional fees were $262,366 as compared to $222,999 for the year ended March 31, 2024, an increase of $39,367. The Increase in professional fees mainly to an increase in accounting and consulting fees.”
see in full comparison
Reworded

Paragraph as it now reads, with added and removed wording marked:

For the year ended March 31, 2025,2026, we incurred total research and development expenses of $180,987$125,079 as compared to $175,268$180,987 for our year ended March 31, 2024,2025, ana increasedecrease of $5,719.$55,908. The increasedecrease was mainly related to an increase in R&D consultingconsulting, costs.offset by a decrease in supplies and materials and patent maintenance.
see in full comparison
Removed text
“Subsequent to March 31, 2025, Gray’s Peak extended the due date of the Note (see Note 3) by six months. As such, the new maturity date is December 31, 2025.”
see in full comparison
Full comparison: every changed paragraph (12)

Green = added, red = removed. Unchanged paragraphs, 4 paragraphs where only numbers/dates changed, and tables are not shown. Read the complete text in the original filing.

Added

For the year ended March 31, 2026, professional fees were $252,036 as compared to $262,366 for the year ended March 31, 2025, a decrease of $10,330.

Removed

For the year ended March 31, 2025, professional fees were $262,366 as compared to $222,999 for the year ended March 31, 2024, an increase of $39,367. The Increase in professional fees mainly to an increase in accounting and consulting fees.

Reworded

For the year ended March 31, 2025,2026, we incurred total research and development expenses of $180,987$125,079 as compared to $175,268$180,987 for our year ended March 31, 2024,2025, ana increasedecrease of $5,719.$55,908. The increasedecrease was mainly related to an increase in R&D consultingconsulting, costs.offset by a decrease in supplies and materials and patent maintenance.

Reworded

For the year ended March 31, 2025,2026, general and administrative expenses were $69,898$68,072 as compared to $346,543$69,898 for our year ended March 31, 2024,2025, a decrease of $276,645. The decrease was mainly related to a decrease in royalty fee we incurred related to patents in the prior period, compared to the prior period.$1,826.

Added

For the year ended March 31, 2026, foreign exchange gain was $24,584 as compared to foreign exchange loss of $11,128 for the year ended March 31, 2025.

Removed

For the year ended March 31, 2025 and 2024, foreign exchange loss was $11,128 and $17,929, respectively.

Reworded

For the year ended March 31, 20252026 and 2024,2025, interest expense, net was $42,669$80,106 and $21,034,$42,669, respectively. The net increase in interest expense related to our increase in loan activitybalances during the year ended March 31, 20252026 as compared to our year ended March 31, 2024.2025.

Removed

For the year ended March 31, 2025 and 2024, we received R&D credits totaling $0 and $198,371 related to our R&D efforts that occurred at our Agentix Australia Pty Ltd entity. We did not receive any R&D credits for the comparable period ended March 31, 2025.

Reworded

For the year ended March 31, 2025,2026, cash from financing was $100,00$110,450 versus $93,000$100,000 for our year ended March 31, 2024.2025. Cash from financings during the year ended March 31, 20252026 and 2025, respectively, consisted of $110,450 and $100,000 from loan proceeds received. Cash from financings during the year ended March 31, 2024 consisted of $163,000 from loan proceeds received offset by our payment of $70,000 on our loans.

Reworded

Our consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. As reflected in our consolidated financial statements for the year ended March 31, 2025,2026, we had an accumulated deficit,deficit of $7,007,164, we did not incur any revenue and we had a net loss along with negative cash generated from our operations. In addition, we owe our vendors and related parties $3,204,523$3,596,282 as of March 31, 2025.2026. Although, on January 15, 2023 and June 15, 2023, we entered into two separate Mezzanine Secured Note (“Notes”) in the principal amount up to $200,000 and $500,000, respectively, with Gray’s Peak Private Credit LLC (see Note 3 to the consolidated financial statements), the debt maturity of these Notes is short term. These factors raise substantial doubt about our ability to continue as a going concern.

Removed

Subsequent to March 31, 2025, Gray’s Peak extended the due date of the Note (see Note 3) by six months. As such, the new maturity date is December 31, 2025.

Reworded

In accordance with ASC 855, we have analyzed our operations subsequent to March 31, 20252026 through the date these financial statements were issued, and have determined that we don’tdo not have any other material subsequent events to disclose in these financial statements.

What changed in the latest 10-Q

Comparing 10-Q filed 2026-08-10 (period ending 2026-06-30) with 10-Q filed 2026-02-17 (period ending 2025-12-31).

Risk Factors (10-Q Part II, Item 1A)

0new paragraphs
0removed paragraphs
0reworded paragraphs
29 → 29words in section

The section in the latest 10-Q reads in full:

As a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act), we are not required to provide the information called for by this Item 1A.

No wording changes found in this section.

Full comparison: every changed paragraph (0)

Green = added, red = removed. Unchanged paragraphs and tables are not shown. Read the complete text in the original filing.

Management's Discussion & Analysis (MD&A) (10-Q Part I, Item 2)

1new paragraphs
10removed paragraphs
12reworded paragraphs
1,661 → 1,241words in section

Removed heading “Nine Months Ended December 31, 2025 as compared to Nine Months Ended December 31, 2024:”

Largest changes (selected automatically by length and topic keywords; quoted verbatim, no commentary)

Removed text
“Nine Months Ended December 31, 2025 as compared to Nine Months Ended December 31, 2024:”
see in full comparison
Reworded topics: securities and exchange commission

Paragraph as it now reads, with added and removed wording marked:

The following information should be read in conjunction with (i) the unaudited consolidated financial statements of Agentix Corp., a Nevada corporation (the “Company”), and development stage company, and the notes thereto appearing elsewhere in this Form 10-Q together withand (ii) the more detailed business information and theaudited March 31, 2025 auditedconsolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K (File No. 000-55383;for the “Formfiscal 10-K”),year asended filedMarch with31, the Securities and Exchange Commission.2026. Statements in this section and elsewhere in this Form 10-Q that are not statements of historical or current fact constitute “forward-looking” statements.
see in full comparison
Reworded

Paragraph as it now reads, with added and removed wording marked:

Three Months Ended DecemberJune 31,30, 20252026 as compared to Three Months Ended DecemberJune 31,30, 20242025:
see in full comparison
Reworded

Paragraph as it now reads, with added and removed wording marked:

Our unaudited consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets,assets and liquidation of liabilities in the normal course of business. As reflected in our unaudited consolidated financial statements for the ninethree months ended DecemberJune 31,30, 2025,2026, we had an accumulated deficit,deficit weof had$7,124,838, a net loss alongof with$117,674, negativenet cash generatedused fromin ouroperating operationsactivities andof we have a$26,372, negative working capital.capital Inof addition,$3,713,793, wecash oweof our vendors$38, and relatedtotal partiescurrent $3,504,397liabilities of $3,713,831 as of December 31, 2025. Although, on January 15, 2023 and June 15,30, 2023, we entered into two separate Mezzanine Secured Note (“Notes”) in the principal amount up to $200,000 and $500,000, respectively, with Gray’s Peak Private Credit LLC (see Note 3 to the unaudited consolidated financial statements), the debt maturity of these Notes is short term.2026. These factors raise substantial doubt about our ability to continue as a going concern.
see in full comparison
Removed text
“As a result, net loss for the three months ended December 31, 2025 was $78,595, as compared to a net loss of $143,894 for the three months ended December 31, 2024. Other comprehensive loss for the three months ended December 31, 2025 included a favorable foreign currency translation adjustment of $1,367 (compared to an unfavorable $63,927 in the prior-year period), resulting in total comprehensive loss of $79,962 versus $79,967 in the prior-year period.”
see in full comparison
Reworded

Paragraph as it now reads, with added and removed wording marked:

As a result, net loss for the ninethree months ended DecemberJune 31,30, 20252026 was $408,526, as$117,674 compared towith a net loss of $385,280$185,824 for the ninethree months ended DecemberJune 31,30, 2024.2025. Other comprehensive loss for the ninethree months ended DecemberJune 31,30, 20252026 included an unfavorable foreign currency translation adjustment of $14,775$608, (compared towith ana unfavorablefavorable $28,759adjustment inof $18,307 for the prior-year period),period, resulting in total comprehensive loss of $393,751$118,282 versusand $356,521$167,517, in the prior-year period.respectively.
see in full comparison
Full comparison: every changed paragraph (23)

Green = added, red = removed. Unchanged paragraphs and tables are not shown. Read the complete text in the original filing.

Reworded

The following information should be read in conjunction with (i) the unaudited consolidated financial statements of Agentix Corp., a Nevada corporation (the “Company”), and development stage company, and the notes thereto appearing elsewhere in this Form 10-Q together withand (ii) the more detailed business information and theaudited March 31, 2025 auditedconsolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K (File No. 000-55383;for the “Formfiscal 10-K”),year asended filedMarch with31, the Securities and Exchange Commission.2026. Statements in this section and elsewhere in this Form 10-Q that are not statements of historical or current fact constitute “forward-looking” statements.

Reworded

Our unaudited consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and with the rules and regulations of the SEC applicable to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are,that, in the opinion of management, are necessary tofor a fair statement of the results for the interim periods presented. Unaudited interim results are not necessarily indicative of the results for the full fiscal year. These financial statements should be read in conjunction with ourthe audited consolidated financial statements for the reporting period ended March 31, 2025 and notes thereto containedincluded in our Annual Report on Form 10-K.10-K for the fiscal year ended March 31, 2026.

Reworded

Three Months Ended DecemberJune 31,30, 20252026 as compared to Three Months Ended DecemberJune 31,30, 20242025:

Reworded

We recorded no revenuesrevenue during the three months ended DecemberJune 31,30, 20252026 and 2024.2025.

Reworded

For the three months ended DecemberJune 31,30, 2025,2026, professional fees were $50,678 as$62,084 compared towith $56,632$82,625 for the three months ended DecemberJune 31,30, 2024,2025, a decrease of $5,954.$20,541. The increase in professional feesdecrease was mainlyprimarily due to higherlower accountingprofessional andservice consultingcosts fees.during the current period.

Reworded

For the three months ended DecemberJune 31,30, 2025,2026, research and development expenses were $0,$16,635 compared towith $23,287$100,000 for the same period in 2024,2025, reflecting ana decrease of $23,287.$83,365. The decrease was mainly related to reducedlower R&Dresearch consultingand costs.development activity during the current period.

Reworded

For the three months ended DecemberJune 31,30, 2025,2026, general and administrative expenses were $16,785 as compared towith $16,896$17,717 for the three months ended DecemberJune 31,30, 2024,2025, a slight decrease of $111.$932, Thereflecting decrease was primarily related toslightly lower software and other administrative costs.

Reworded

ForThe theCompany threerecorded months ended December 31, 2025,no foreign exchange gain was $2,672 compared to aor loss of $35,784 for the three months ended DecemberJune 31,30, 2024,2026, compared with a $38,456foreign lessexchange favorablegain of $15,140 for the three months ended June 30, 2025, a $15,140 unfavorable variance due primarily to fluctuations in currency exchange rates.

Removed

For the three months ended December 31, 2025, interest expense, net was $13,804 as compared to $11,295 for the three months ended December 31, 2024. The increase of $2,509 related to higher average borrowings and related financing costs during the period.

Removed

For the three months ended December 31, 2025, other income was $0 (no comparable amount in the prior-year quarter).

Removed

As a result, net loss for the three months ended December 31, 2025 was $78,595, as compared to a net loss of $143,894 for the three months ended December 31, 2024. Other comprehensive loss for the three months ended December 31, 2025 included a favorable foreign currency translation adjustment of $1,367 (compared to an unfavorable $63,927 in the prior-year period), resulting in total comprehensive loss of $79,962 versus $79,967 in the prior-year period.

Removed

Nine Months Ended December 31, 2025 as compared to Nine Months Ended December 31, 2024:

Removed

We recorded no revenues during the nine months ended December 31, 2025 and 2024.

Removed

For the nine months ended December 31, 2025, professional fees were $214,536 as compared to $197,942 for the nine months ended December 31, 2024, an increase of $16,594. The increase in professional fees was mainly due to higher accounting, legal and consulting support.

Removed

For the nine months ended December 31, 2025, research and development expenses were $125,079 as compared to $90,638 for the same period in 2024, an increase of $34,441, primarily related to increased R&D consulting and project activity.

Removed

For the nine months ended December 31, 2025, general and administrative expenses were $51,287 as compared to $52,550 for the nine months ended December 31, 2024, a decrease of $1,263, reflecting cost controls and lower software and overhead expenses.

Removed

For the nine months ended December 31, 2025, foreign exchange gain was $20,961 compared to a loss of $15,376 for the nine months ended December 31, 2024, a $36,337 less favorable variance due primarily to currency fluctuations.

Reworded

For the ninethree months ended DecemberJune 31,30, 2025,2026, interest expense, net was $59,189 as$22,170 compared towith $28,774$21,226 for the ninethree months ended DecemberJune 31,30, 2024,2025, an increase of $30,415,$944 related to higher average debt balances and related financingaccrued costs.interest.

Added

For the three months ended June 30, 2026, other income was $0 compared with $20,604 for the three months ended June 30, 2025. The prior-year amount related to a gain on settlement of payables.

Removed

For the nine months ended December 31, 2025, other income was $20,604, consisting primarily of a gain recognized on the settlement of accounts payable (no comparable amount in the prior-year period).

Reworded

As a result, net loss for the ninethree months ended DecemberJune 31,30, 20252026 was $408,526, as$117,674 compared towith a net loss of $385,280$185,824 for the ninethree months ended DecemberJune 31,30, 2024.2025. Other comprehensive loss for the ninethree months ended DecemberJune 31,30, 20252026 included an unfavorable foreign currency translation adjustment of $14,775$608, (compared towith ana unfavorablefavorable $28,759adjustment inof $18,307 for the prior-year period),period, resulting in total comprehensive loss of $393,751$118,282 versusand $356,521$167,517, in the prior-year period.respectively.

Reworded

Our unaudited consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets,assets and liquidation of liabilities in the normal course of business. As reflected in our unaudited consolidated financial statements for the ninethree months ended DecemberJune 31,30, 2025,2026, we had an accumulated deficit,deficit weof had$7,124,838, a net loss alongof with$117,674, negativenet cash generatedused fromin ouroperating operationsactivities andof we have a$26,372, negative working capital.capital Inof addition,$3,713,793, wecash oweof our vendors$38, and relatedtotal partiescurrent $3,504,397liabilities of $3,713,831 as of December 31, 2025. Although, on January 15, 2023 and June 15,30, 2023, we entered into two separate Mezzanine Secured Note (“Notes”) in the principal amount up to $200,000 and $500,000, respectively, with Gray’s Peak Private Credit LLC (see Note 3 to the unaudited consolidated financial statements), the debt maturity of these Notes is short term.2026. These factors raise substantial doubt about our ability to continue as a going concern.

Reworded

In accordance with ASC 855, wethe haveCompany has analyzed ourits operations subsequent to DecemberJune 31,30, 20252026 through the date these financial statements were issued,issued and havehas determined that weit don’tdoes not have any other material subsequent events to disclose in these financial statements.

AGTX insider buying and selling (Form 4)

Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 0 filings. Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.

No Form 4 stock transactions in this period.

Well-known investors holding AGTX (13F)

None of the 59 investors we track reported a position in their latest 13F.

Coming soon: email alerts when AGTX files, watchlists and downloadable comparisons.